Immune Modulation to Improve Tissue Engineering Outcomes for Cartilage Repair in the Osteoarthritic Joint

Niamh Fahy, MSc,¹ Eric Farrell, PhD,^{1,2} Thomas Ritter, PhD,¹
Aideen E. Ryan, PhD,¹ and J. Mary Murphy, PhD¹

Osteoarthritis (OA), the most common form of arthritis, is a disabling degenerative joint disease affecting synovial joints and is associated with cartilage destruction, inflammation of the synovial membrane, and subchondral bone remodeling. Inflammation of the synovial membrane may arise secondary to degenerative processes in articular cartilage (AC), or may be a primary occurrence in OA pathogenesis. However, synovial inflammation plays a key role in the pathogenesis and disease progression of OA through the production of pro-inflammatory mediators, and is associated with cartilage destruction and pain. The triggers that initiate activation of the immune response in OA are unknown, but crosstalk between osteoarthritic chondrocytes, cartilage degradation products, and the synovium may act to perpetuate this response. Increasing evidence has emerged highlighting an important role for pro-inflammatory mediators and infiltrating inflammatory cell populations in the progression of the disease. Tissue engineering strategies hold great potential for the repair of damaged AC in an osteoarthritic joint. However, an in-depth understanding of how OA-associated inflammation impacts chondrocyte and progenitor cell behavior is required to achieve efficient cartilage regeneration in a catabolic osteoarthritic environment. In this review, we will discuss the role of inflammation in OA, and investigate novel immune modulation strategies that may prevent disease progression and facilitate successful cartilage regeneration for the treatment of OA.

Introduction

OSTEARTHRTIS (OA) IS A COMPLEX disease of synovial joints that is associated with chronic pain and reduced joint mobility. It is an age-related condition, with known risk factors for disease development including high body mass index, particularly in young adults, and previous joint injury.^{1–3} OA is characterized by cartilage breakdown, but the disease process affects various joint structures involving inflammation of the synovial membrane and subchondral bone remodeling. Therefore, it has been suggested by Loefer *et al.* and others that OA should be considered a disease of the entire joint as an organ.⁴

An imbalance of cellular homeostasis is an important feature of OA, with mechanical stress and pro-inflammatory cytokines postulated to contribute to this change. Cell proliferation and enhanced matrix remodeling in bone and cartilage are also major features, and the formation of new bone at the joint margins.^{5,6} Articular chondrocytes increase expression of matrix molecules, and catabolic factors including matrix metalloproteinases (MMPs), ADAMTs (a disintegrin and metalloproteinase with thrombospondin motifs), and pro-inflammatory cytokines. Chondrocytes suffer a loss of char-

acteristic phenotype due to loss of extracellular matrix (ECM) components and structure, and undergo hypertrophy and terminal differentiation.⁵ Decreased accumulation of sulphated proteoglycans and collagen type II has been observed in osteoarthritic cartilage compared to healthy.⁶ Increasing evidence highlights the importance of factors produced by inflamed synovium to the initiation and progression of the disease and inflammation of the synovial membrane with increased vascular density and cellular infiltration is a prominent feature of OA pathogenesis.⁷ Additionally, pro-inflammatory mediators detected in synovial fluid of OA joints are known to stimulate degradation of cartilage and inhibit matrix synthesis.^{8–13} Inflammation of the synovial membrane may be a primary occurrence in disease pathogenesis, with thickening of the synovial membrane identified by MRI in patients with early stage and mild OA.¹⁴ Alternatively, synovial inflammation may be secondary to degenerative processes in articular cartilage (AC), with the release of cartilage degradation products activating immune and synovial cells and initiating an inflammatory response (Fig. 1).

Tissue engineering strategies can be harnessed to promote repair of damaged AC in an osteoarthritic joint. However, it is clear that interplay between joint tissues and pro-inflammatory

¹Regenerative Medicine Institute, National University of Ireland Galway, Galway, Ireland.

²Department of Oral and Maxillofacial Surgery, Special Dental Care and Orthodontics, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands.

FIG. 1. Schematic representation of inflammatory processes associated with the pathogenesis of osteoarthritis (OA). Activation of resident synoviocytes by cartilage degradation products or pro-inflammatory mediators, and infiltration of the synovium by immune cells, may induce destructive processes in cartilage and drive disease progression. Color images available online at www.liebertpub.com/teb

mediators contributes to the loss of cellular homeostasis that is associated with disease progression. Therefore, inflammatory processes associated with OA need to be addressed to achieve successful cartilage repair in the osteoarthritic environment. In this review, we will examine the role of inflammation in OA and explore novel immune modulation approaches, which may halt disease progression and facilitate successful cartilage regeneration in the osteoarthritic environment.

Tissue Engineering Applications in OA

Current approaches for the treatment of AC damage resulting from OA include bone marrow stimulation techniques such as microfracture.¹⁵ This method involves drilling or abrasion of subchondral bone and subsequent release of progenitor cells from the bone marrow to induce repair. However, generation of suboptimal reparative fibrocartilage may occur, which limits the effectiveness of this technique for repair of AC defects and restoration of function.¹⁶ Regenerative procedures such as osteochondral autografting (mosaicplasty), autologous chondrocyte implantation (ACI), and matrix-induced autologous chondrocyte implantation (MACI) are considered favorable therapeutic strategies, given their potential for the generation of hyaline cartilage.^{17–19} ACI involves the use of cultured autologous chondrocytes harvested from a nonweight bearing region of the knee, to resurface chondral defects.¹⁸ In the case of MACI, chondrocytes are seeded on to a type I/III collagen scaffold for implantation.¹⁹ Both ACI and MACI have been found to be superior to microfracture for the treatment of larger articular defects.^{20,21} However, the current standard for treatment of severe joint injuries and advanced OA still involves partial or total joint replacements.

New tissue engineering/regenerative medicine (TERM) strategies such as direct intra-articular delivery of progenitor cells, progenitor cell delivery on scaffolds or cell-free scaffolds coated with biological factors for recruitment of endogenous cells have been investigated for AC repair.^{22–24}

The use of cell-based therapeutics such as mesenchymal stem cells (MSCs) has been extensively studied for efficacy in OA.²⁵ MSCs are considered a favorable cell source for therapeutic applications in joint repair due to their chondrogenic differentiation capacity and paracrine effects on host cells.^{26,27} Intra-articular injection of autologous MSCs in to the knee joints of patients with OA has been well tolerated and a significant reduction in pain has been observed, with paracrine anti-inflammatory activity of MSCs postulated to contribute to this outcome.^{28–30} Furthermore, treatment of patients undergoing partial meniscectomy surgery with an intra-articular injection of allogeneic MSCs has resulted in meniscal regeneration as well as a significant reduction in pain.³¹ To achieve successful regeneration with tissue engineering approaches in an osteoarthritic joint, an in-depth understanding is required of how OA-associated inflammation impacts chondrocyte and progenitor cell behavior. Addressing inflammatory processes in OA with TERM strategies may not only facilitate successful repair but halt the progressive destruction of an OA joint.

Inflammation in OA

Inflammation of the synovial membrane is a prominent feature of OA pathogenesis (Fig. 1), and increasing evidence highlights the role of cells of the innate and acquired immune system, and other inflammatory components, in disease progression. The innate immune system functions as a frontline of defence, involving cells such as macrophages, dendritic cells, and neutrophils, which act to recognize invading pathogens and elicit an antimicrobial and pro-inflammatory response.³² The interaction between these antigen-presenting cells of the innate immune system and T lymphocytes is vital for the activation of T cell-dependent responses of the acquired immune system, which function to eliminate infected cells or further propagate inflammation.³³ The synovial membrane is characterized by a lining layer

containing macrophages and fibroblasts, termed synovio-cytes, and CD68⁺ macrophages and T lymphocytes, generally described as CD3⁺ T cells, have been identified as the most abundant immune cells in infiltrates present in OA synovium.³⁴ An in-depth understanding of the role played by each cell type implicated in the propagation of inflammation in OA may allow for the development of therapeutic strategies for modulation of the pro-inflammatory milieu and facilitate successful tissue regeneration.

Synovitis

The synovial membrane is an area of high functional importance within the joint, responsible for nourishing chondrocytes and removing metabolites. Inflammation of the synovium results in synovitis, which is believed to reflect structural progression of OA.³⁵ Synovial hypertrophy and hyperplasia are associated with synovial inflammation, and synovitis may contribute to the catabolism of cartilage through pro-inflammatory mediator production. Joint injury has been reported to increase the risk of developing OA and traumatic knee meniscal injuries are associated with synovial inflammation.^{36,37} Long-term coculture models of synovial tissue and cartilage explants highlight the role of activated synovio-cytes in cartilage destruction associated with OA.³⁸ The synovial tissue was found to secrete high levels of interleukin (IL)-6, IL-8, and osteoprotegerin, and to produce cytokines throughout the culture period. Furthermore, cartilage explant glycosaminoglycan (GAG) content was found to be significantly lower following a 21-day exposure to the synovial tissue compared with cartilage monocultures.³⁸ It is evident that pro-inflammatory mediators produced by inflamed synovium are capable of driving the progression of OA through induction of destructive processes in cartilage (Table 1), and the abundance of such catabolic factors in an osteoarthritic joint may greatly impede cartilage tissue engineering strategies.

Synovial macrophages

Synovial macrophages, which are localized to the lining and sublining synovial layers, are considered primary cel-

lular mediators of synovial inflammation in an OA joint.³⁹ These cells are capable of phagocytosis and antigen presentation, and they play a prominent role in the production of the pro-inflammatory cytokines tumor necrosis factor- α (TNF- α), IL-1 β , IL-6, and oncostatin M.^{38,40–42} IL-1 β and TNF- α induce destructive processes in chondrocytes associated with OA pathology including downregulation of collagen type II and proteoglycan, and upregulation of MMP-9 and cyclooxygenase-2 (COX-2).⁴³ The enzyme COX-2 functions in the production of prostaglandins, which are known to play a role in pain and inflammation, and COX-2 expression is elevated in multiple immune cell types.⁴⁴ Moreover, IL-1 β induces COX-2 and prostaglandin E2 (PGE2) expression in human chondrocytes and is associated with cartilage matrix calcification.⁴⁵

In addition to pro-inflammatory cytokine production, macrophages secrete high mobility group box protein 1 (HMGB1) as a late mediator of inflammation following stimulation with TNF, IL-1 β , and lipopolysaccharide (LPS).⁴⁶ Secretion of HMGB1 can occur in response to pro-inflammatory signals, resulting in pro-inflammatory cytokine-like activity of HMGB1, whereby it may further propagate inflammatory responses.⁴⁷ HMGB1 expression has been detected in both normal and osteoarthritic synovio-cytes, and it was found to act in synergy with IL-1 β to amplify the expression of pro-inflammatory mediators.^{48,49} Additionally, HMGB1 has been shown to have synergistic activity on TNF, IL-8, IL-6, and MMP-3 production by OA synovial fibroblasts when added to cultures in preformed complexes with LPS and IL-1 β . In addition to propagating inflammatory responses, HMGB1 may promote destructive effects in joint tissues. The release of HMGB1 by chondrocytes has been reported by Taniguchi *et al.* to act as a chemoattractant for osteoblasts and osteocytes, regulating endochondral bone formation.⁵⁰ The process of endochondral ossification is a feature of osteophyte formation in OA, and endochondral signaling resulting from HMGB1 secretion may play an additional role in progression of the disease.^{51,52} Synovial macrophages have been identified as key players mediating osteophyte formation in OA, with a significant reduction in TGF- β -induced osteophyte formation observed following the depletion of synovial macrophages utilizing clodronate liposomes.^{53,54}

TABLE 1. INFLAMMATORY MEDIATORS THAT NEGATIVELY IMPACT JOINT STRUCTURES

Mediator	Effects	References
IL-1 β	Catabolic effects on cartilage phenotype: decreases collagen type II and proteoglycan, increases PGE2, MMP-9, and COX-2 Induces cartilage matrix calcification through the expression of transglutaminases	Wang <i>et al.</i> ⁴⁵ Li <i>et al.</i> ¹² Johnson <i>et al.</i> ¹³
TNF- α	Induces catabolic and pro-inflammatory enzymes: COX-2 and MMP-9 Decreases cartilage-specific gene expression: reduces expression of ECM genes and aggrecan	Shakibaei <i>et al.</i> ⁴³ Dvir-Ginzberg <i>et al.</i> ¹⁰ Westacott <i>et al.</i> ¹¹
TGF- β	Contributes to cartilage matrix degradation and focal loss of cartilage Induces osteophyte formation Associated with changes in subchondral bone architecture	Scharstuhl <i>et al.</i> ¹³⁸ Zhen <i>et al.</i> ¹³⁹
IL-6	Downregulation of collagen type II and aggrecan in articular chondrocytes	Legendre <i>et al.</i> ⁹
HMGB1	Amplifies expression of pro-inflammatory mediators Synergistic activity with IL-1 β on amplifying IL-6, IL-8, MMP-1, and MMP-3 by synovio-cytes	Yang <i>et al.</i> ⁴⁷ Garcia-Arnandis <i>et al.</i> ⁴⁸

COX-2, cyclooxygenase-2; ECM, extracellular matrix; HMGB1, high mobility group box protein 1; IL, interleukin; MMP, matrix metalloproteinases; PGE2, prostaglandin E2; TNF- α , tumor necrosis factor- α .

Synovial fibroblasts

Inflammatory mediators produced by synovial macrophages may induce activation and further pro-inflammatory mediator production by neighboring synoviocytes. OA synovial fibroblasts have been reported to produce IL-6, IL-8, macrophage colony stimulating factor, and vascular endothelial growth factor (VEGF) in response to IL-1 β stimulation.⁵⁵ Furthermore, the AC pericellular matrix protein Laminin-111 may bind to and activate synovial fibroblasts in the presence of TGF- β 1, which was found to result in IL-6 and IL-8 secretion, a mechanism by which synovial fibroblasts may contribute to disease pathology outside periods of acute inflammation.^{56,57} Synovial fibroblasts also upregulate expression of vascular cell adhesion molecule-1 (VCAM-1) in response to chemokine (C-C motif) ligand 2 (CCL2) and CCN family member 4, both of which are detected in synovial fluid of patients with OA. This process may facilitate the adhesion of mononuclear cells to the site of inflammation.^{58,59} These findings indicate that synovial fibroblasts may contribute to synovial inflammation through propagating inflammatory responses following activation by pro-inflammatory mediators, or by facilitating the adhesion of infiltrating immune cells. However, the contribution of synovium to the progression of OA appears to be primarily mediated by inflammatory cells including resident macrophages and infiltrating immune populations.

Mast cells

Mast cells are also considered to play a role in contributing to inflammation associated with OA. Elevated mast cell counts in the synovial fluid of patients with OA have been reported, with higher levels of histamine, tryptase, and nitrite detected in OA synovial fluid.^{60,61} Furthermore, a role for TNF- α in the induction of mast cell chemotaxis in OA has been elucidated.⁶² Studies have suggested that the observed increase of mast cells in OA may be due to the expansion of a tryptase but not chymase containing population, with an increase in this population reported in the synovial tissue of OA patients compared with control.⁶³ The serine protease tryptase is released from mast cells upon degranulation along with other products including heparin, histamine, and many proteases.⁶⁴ Tryptase can induce IL-8 release and expression of the adhesion molecule intercellular adhesion molecule 1 (ICAM-1) by epithelial cells and upregulate IL-8 and IL-1 β gene expression in endothelial cells, suggesting a potential role of tryptase in the propagation of inflammatory responses through cellular recruitment.^{65,66}

The complement system

The complement system is an essential component of the innate immune system, functioning to eliminate macromolecules and foreign bodies by opsonization or cell lysis.⁶⁷ A role of complement activation in the pathogenesis of OA has been elucidated, with increased gene expression of complement factors in OA synovium reported.⁶⁸ This group pursued studies utilizing a medial meniscectomy model of OA with mice genetically deficient in complement components C5, C6, and CD59a, to reveal that the membrane attack complex of the complement pathway was involved in the development of the disease. Proteomic studies identified

differential expression of complement proteins in human OA synovial fluid compared to control, further suggesting a potential role of these proteins in catabolic processes associated with OA.⁶⁹

T cells

Infiltrating CD3⁺ T cells have been detected in the synovial perivascular area of patients with early stage disease.⁷⁰ Furthermore, T cells expressing antigens of early, intermediate, and late activation have been detected in the synovium of patients with advanced OA.⁷¹ CD4⁺ effector T cells may be classified according to several subsets, with varying immunological functions associated with their characteristic cytokine expression profile. Cells of the T helper 1 (Th1) subset are associated with production of IL-2 and interferon (IFN)- γ , and can establish cell-mediated inflammatory responses such as macrophage and cytotoxic T-cell activation, which functions to clear intracellular pathogens.^{72,73} Conversely, cells of the T helper 2 (Th2) subset express IL-4, IL-5, and IL-10, resulting in increased antibody production, and elimination of parasitic infections.^{73–75} Detection of CD4⁺ effector T cells and CD8⁺ cytotoxic T cells, predominantly in the sublining layer of synovium from patients with OA has been reported.⁷⁶ Furthermore, increased levels of IFN- γ and IL-2 were detected compared with IL-4, suggesting a prevalence of Th1 cells.^{71,76} In additional studies, infiltration of CD4⁺ effector T cells and macrophages were found in association with increased expression levels of VEGF and abundant ICAM-1 expression in early OA synovial tissue.⁴⁰ VEGF is expressed by macrophages and known to induce endothelial cell chemotaxis and mediating vascular permeability, an important process in inflammation.^{77–79} Interestingly, intra-articular injection of VEGF in mice has increased calcification of AC, cartilage degradation, and subchondral bone sclerosis, implicating a role of VEGF in OA.⁸⁰ ICAM-1 is upregulated by osteoarthritic synoviocytes in response to pro-inflammatory stimuli and plays an important role in transendothelial migration of T cells and may therefore mediate the migration and infiltration of lymphocytes in the synovium.^{81,82}

Using CD4⁺ T cell depletion in a murine anterior cruciate ligament-transection (ACLT) model for induction of OA, Shen *et al.* elegantly identified a role for CD4⁺ T cells in the pathogenesis of the disease.⁸³ Increased levels of infiltrating CD4⁺ T cells were evident in the synovium and localized throughout the membrane 30 days after ACLT alone. Increased synovial expression of the chemokine macrophage inflammatory protein (MIP)-1 γ was detected in the ACLT group compared with the CD4⁺ T cell depleted ACLT model. Furthermore, T-cell depletion was found to correlate with increased levels of IL-4 and tissue inhibitor of metalloproteinase-1. T cells may further play a role in OA disease progression and contribute to inflammation through the recognition of cartilage matrix molecules, with aggrecan epitopes previously identified as targets of self-reactive T cells in patients with OA.⁸⁴

Current Pharmacological Agents Targeting Inflammation in OA

Current anti-inflammatory therapies recommended for the management of knee and hip OA include COX-2 selective and

nonselective nonsteroidal anti-inflammatory drugs (NSAIDs).⁸⁵ Although these pharmacological agents have been reported to provide analgesia and reduce inflammation following short-term treatment,⁸⁶ long-term use is associated with adverse side effects, including gastrointestinal toxicity and increased risk of cardiovascular events.^{87,88} Furthermore, Reijman *et al.* have reported that NSAIDs use may increase progression of OA,⁸⁹ and certain NSAIDs have been found to negatively impact collagen metabolism and GAG synthesis.^{90,91} Although administration of NSAIDs and COX-2 inhibitors provide symptomatic relief, the ability of these agents to limit disease progression remains to be seen.

Novel pharmacological agents have been developed to target inflammatory mediators associated with OA pathology. A TNF- α -binding antibody, Adalimumab, has been reported to decrease the progression of structural damage in inflamed joints of patients with erosive hand OA, however, an effect on inflammation was not observed.⁹² Other groups have found this TNF- α antagonist to provide symptomatic relief for patients with knee OA, including an improvement in pain and swelling.⁹³ However, the ability of this therapy to slow down the development of structural damage in the OA knee requires further investigation. Additional studies performed to target pro-inflammatory cytokines associated with OA pathogenesis have generated mixed results. Symptomatic efficacy of the IL-1 inhibitor Diacerein for treatment of knee and hip OA has been reported.^{94,95} However, no significant improvement in symptoms was observed following intra-articular injection of a recombinant form of IL-1-receptor antagonist (IL-1RA) to patients with knee OA.⁹⁶ It appears that the potential of current anti-inflammatory therapies to improve structural damage is limited, and the development of novel immune modulation strategies is required to alter the progression of OA.

The Effect of Inflammation on Tissue Engineered Cartilage

As previously discussed, TERM-based strategies may represent the key to improved cartilage regeneration both in isolated defects and treatment of OA. However, it is evident that inflammation plays a significant role in OA pathogenesis and the immune response is increasingly recognized as a key factor influencing tissue regeneration. For example, disorders such as diabetes mellitus that are associated with an inflammatory state are also characterized by impaired tissue regeneration.⁹⁷ TERM strategies for cartilage regeneration may be compromised as a result of dysregulated inflammatory processes and pro-inflammatory mediators in the joint. IL-1 β has been reported to reduce collagen type 2 expression and GAG content of human nasal and articular chondrocytes cultured on a type 1 collagen scaffold,⁹⁸ and both IL-1 β and TNF- α have been shown to impact the integration of engineered cartilage with native tissue.⁹⁹ Additionally, these pro-inflammatory cytokines have been shown to inhibit the migratory potential of chondrogenic progenitor cells in osteoarthritic cartilage,¹⁰⁰ which may limit the success of strategies utilizing cell-free scaffolds for recruitment of endogenous cells and *in situ* cartilage regeneration.²⁴

In addition to directly impacting engineered cartilage and endogenous cellular repair, inflammation may also hinder stem cell-based repair strategies. Previous studies have re-

ported a detrimental effect of IL-1 β and TNF- α on chondrogenic differentiation of MSCs in aggregate culture.¹⁰¹ Furthermore, IL-1 α treatment of chondrogenically differentiating MSCs seeded on a 3D woven poly(ϵ -caprolactone) scaffold, has been shown to decrease accumulation of ECM components and reduce the mechanical properties of the construct.¹⁰² In addition to these findings, OA synovium-conditioned medium and synovial fluid have been shown to inhibit MSC chondrogenesis.^{103,104} It is evident that modulation of the inflammatory environment in an OA joint is vital to maintain the integrity of engineered cartilage, or achieve efficient cell-based repair.

Tissue Engineering Strategies for Immunomodulation in OA

Given that the inflammatory milieu may determine the success of tissue regeneration strategies, regulation of inflammatory processes in the OA joint is required to achieve successful cartilage repair. TERM-based strategies such as the use of biomaterials with immunomodulatory capacity, the delivery of cells and anti-inflammatory proteins, or gene therapy approaches may serve as favorable strategies for gaining control over the pro-inflammatory environment present in OA and subsequently interfere with the disease process.

Biomaterials

The use of biomaterials as a scaffold for the delivery of cells or proteins with immunomodulatory capacity may serve as an efficient strategy to attenuate disease progression in OA and facilitate successful tissue regeneration. However, implantation of biomaterials may induce local tissue injury and inflammation.¹⁰⁵ Studies performed by Grotenhuis *et al.*, have assessed the effect of different biomaterials on macrophage responses *in vitro*, and found that biomaterials alone have the ability to influence macrophage inflammatory phenotype.¹⁰⁶ Additionally, nanocrystalline hydroxyapatites have been reported to increase pro-inflammatory cytokine production by macrophages, indicating activation of the innate immune system.¹⁰⁷ In light of these findings, it is apparent that the interaction of biomaterials with immune cells, such as macrophages, needs to be carefully considered to avoid exacerbating existing inflammation. Anti-inflammatory α -melanocyte-stimulating hormone coated poly (D, lactic-co-glycolic) acid microspheres have been reported to modulate biomaterial-induced inflammation following subcutaneous implantation in rats.¹⁰⁸ However, whether this approach would be beneficial in the context of a chronic inflammatory environment requires further investigation.

Cell therapy

Stem cells such as MSCs are considered a promising cell type for OA cell therapy and cartilage tissue engineering due to their potential to differentiate and replace chondrocytes, as shown using muscle-derived stem cells modified to express BMP-4 and an inhibitor of angiogenesis.^{27,109} However, as previously discussed the presence of an inflammatory environment may impede the use of MSCs in cell replacement strategies. Alternatively, paracrine effects of MSCs may act

to recruit endogenous progenitor cells or be immunomodulatory.¹¹⁰ Trophic factors released by MSCs in response to pro-inflammatory cytokine stimulation have been reported to reduce the expression of IL-1 β , MMP-1, and MMP-13 by OA synovium explants, indicating an anti-inflammatory and anti-catabolic effect of MSCs.¹¹¹ Furthermore, MSCs exert a suppressive effect on activated immune cells and studies investigating the suppressive effect of MSCs on T-cell proliferation have reported a major role of the anti-inflammatory cytokine IL-10 in the suppression of T-cell activation.^{112,113} An immunosuppressive effect of MSCs on mast cells has been demonstrated following coculture experiments, with a decrease in mast cell degranulation, TNF- α production and chemotaxis observed.¹¹⁴ Macrophages exhibit a high degree of plasticity, with the potential to change phenotype according to environmental cues. They can be categorized as classically activated (M1), which produce high levels of pro-inflammatory cytokines or alternatively activated (M2) macrophages, which are associated with anti-inflammatory properties and play a role in wound healing and immune regulation.¹¹⁵ Coculture studies have been performed with MSCs and macrophages to investigate the immunomodulatory capacity of MSCs on macrophage phenotype. MSC-treated macrophages were reported to express the M2 macrophage marker CD206, with increased expression of IL-10, and low expression of the M1-associated cytokines IL-12 and TNF- α .^{116,117} Furthermore, transplanted collagen scaffolds seeded with MSCs and polymer complexed-IL-10 plasmids have resulted in macrophage polarization, with an observed increase in CD63⁺ M2 polarized and a decrease in CD80⁺ M1 polarized macrophages.¹¹⁸ Additionally, delivery of MSCs with IL-10 polyplexes reportedly increased the retention rate of MSCs *in vivo*, which was associated with increased IL-10 levels and decreased pro-inflammatory cytokines.

Intra-articular injection of MSCs has been reported to inhibit the development of posttraumatic arthritis in an intra-articular fracture mouse model, with an increase in systemic IL-10 levels observed.¹¹⁹ Moreover, intra-articular injection of adipose-derived stem cells (ASCs) has been shown to reduce synovial lining thickness and decrease cartilage damage in a collagenase-induced OA mouse model.¹²⁰ ASCs were identified in close proximity to synovial macrophages and reduced IL-1 β gene expression levels were detected in synovial tissue, indicating immunomodulatory activity of these stem cells within the OA joint. In addition to this study, Desando *et al.* have observed reduced synovial lining thickness and cellular infiltration, and decreased cartilage expression of TNF- α following intra-articular injection of ASCs in a rabbit ACLT model.¹²¹ In light of these findings, the use of MSCs or ASCs may serve as a suitable cell therapeutic strategy to attenuate inflammation in OA via paracrine mechanisms and through the modulation of activated immune cells, which contribute to disease pathogenesis.

The use of induced pluripotent stem cells (iPSCs) may provide an additional cell source for cartilage tissue engineering.¹²² iPSCs generated from the reprogramming of mouse fibroblasts have been successfully differentiated toward the chondrogenic lineage, and shown to integrate with native cartilage tissue and produce cartilage matrix in an *in vitro* cartilage defect model.¹²³ Furthermore, chondrogenic differentiation of MSC-like cells derived from human iPSCs has been shown by Guzzo *et al.* to result in a cellular

phenotype that more closely resembles articular chondrocytes, compared with undifferentiated iPSCs.¹²⁴ iPSC-derived MSCs inhibit lymphocyte proliferation and suppress Th2-associated cytokine production in a similar manner to MSCs, and have been found to elicit a comparable immunomodulatory effect in a mouse model of allergic inflammation.^{125,126} Given that MSCs are associated with an age-related reduction in proliferation and differentiation capacity, iPSC-derived MSCs may serve as a useful cell source for large-scale generation of MSCs for cell therapy approaches in OA.¹²⁷

Anti-inflammatory protein delivery

Anti-inflammatory IL-10 has the ability to suppress pro-inflammatory mediator production by activated macrophages.¹²⁸ Various studies on immune modulation by MSCs have implicated IL-10 as an important mediator.¹¹³ Interestingly, synergistic activity of IL-4 with IL-10 has been previously reported.¹²⁹ Recent studies have demonstrated a protective effect of IL-4 in combination with IL-10 on blood-induced cartilage damage compared to IL-10 treatment alone.¹³⁰ The use of these factors may be beneficial to limit cartilage damage resulting from joint bleeding during surgical procedures for treatment of OA-related defects. A study utilizing a rat model of instability-induced experimental OA has reported that IL-4 may have a chondroprotective effect in mechanical stress-induced OA through suppressing nitric oxide production by chondrocytes and preventing cartilage destruction following intra-articular injection.¹³¹ The use of biomaterial scaffolds for localized delivery of anti-inflammatory proteins may be a beneficial strategy to antagonize pro-inflammatory mediator production in an osteoarthritic joint, and subsequently counteract the negative influence of pro-inflammatory mediators on cartilage regeneration.

Gene delivery

Gene therapy approaches for the treatment of cartilage defects in OA have been previously examined. For example, the potential of overexpression of the cartilage transcription factor SOX9 by MSCs for AC repair has been evaluated, utilizing a rabbit full-thickness cartilage defect model.¹³² Improved integration of newly formed tissue with native cartilage and positive staining for type II collagen was reported following implantation of transduced MSCs seeded on a polyglutamic acid scaffold. The therapeutic efficacy of inflammatory mediator overexpression in an OA environment has also been evaluated. A decrease in gross pathologic abnormalities was observed following adenoviral vector-mediated IL-1RA gene delivery, in an equine experimental OA model.¹³³ The effects of retrovirally delivered human IL-1RA and IL-10 have also been assessed following injection in to the knee joint in a rabbit model of OA.¹³⁴ Intra-articular expression of these genes was found to have a chondroprotective effect with an evident reduction in cartilage degradation. Administration of both IL-1RA and IL-10 was reported to have a greater effect, compared with administration of either gene alone. The delivery or overexpression of anti-inflammatory mediators via gene therapy approaches may therefore offer a novel therapeutic strategy for the treatment of OA, through attenuating the destructive effect of inflammation on cartilage (Table 2).

TABLE 2. PRECLINICAL STUDIES UTILIZING GENE DELIVERY WITH THERAPEUTIC POTENTIAL FOR TREATMENT OF OSTEOARTHRITIS

Gene	Vector	Delivery method	Disease model	Species	Effect	Reference
SOX9	Adenovirus	Intra-articular delivery of transduced rabbit bone marrow MSCs	Full-thickness cartilage defect	Rabbit	Induction of MSC chondrogenesis <i>in vitro</i> Newly formed cartilage tissue <i>in vivo</i>	Cao <i>et al.</i> ¹³²
IL-1RA	Adenovirus	Direct vector intra-articular injection	Osteochondral fragment exercise model	Horse	Decrease in gross pathologic abnormalities	Frisbie <i>et al.</i> ¹³³
IL-1RA	Plasmid DNA vector	Direct intra-articular injection of plasmid	Partial medial meniscectomy model	Rabbit	Reduced progression of OA	Fernandes <i>et al.</i> ¹³⁵
IL-1RA	Retrovirus	Intra-articular injection of <i>ex vivo</i> transduced synovioytes	Anterior cruciate ligament resection model	Dog	Reduction of cartilage lesions and reduced progression of OA	Pelletier <i>et al.</i> ¹³⁶
IL-1RA & IL-10	Retrovirus	Intra-articular delivery of transduced rabbit synovioytes	Excision of the medial collateral ligament plus medial meniscectomy	Rabbit	Chondroprotective effect Reduced cartilage degradation	Zhang <i>et al.</i> ¹³⁴
TGF- β 1	Retrovirus	Intra-articular injection of transduced human chondrocytes	Full-thickness cartilage defect model	Goat	Increased chondrocyte proliferation and deposition of collagen type II	Noh <i>et al.</i> ¹³⁷

IL-1RA, IL-1-receptor antagonist; MSCs, mesenchymal stem cells.

Conclusion

Modifying the intra-articular environment in OA through the attenuation of destructive processes affecting cartilage and synovium would offer great therapeutic benefit. Synovial inflammation is a key player in the pathogenesis of OA and is highly associated with cartilage destruction and disease progression. Furthermore, infiltrating inflammatory cell populations play a key role in propagating inflammatory responses. Modulation of synovial inflammation has been shown to impact clinical symptoms and prevent structural damage. The immune response is increasingly recognized as a key factor influencing tissue regeneration, and gaining control of the pro-inflammatory environment associated with OA is vital to achieve efficient tissue repair with TERM-based strategies and halt disease progression. Combining cell-based therapy using MSCs with anti-inflammatory genes to deliver immunomodulatory factors *in vivo*, may serve as a favorable strategy to attenuate destructive inflammatory processes and promote regeneration of cartilage defects in an OA joint.

Acknowledgments

This work was supported by Science Foundation Ireland grant number 09/SRC/B1794, the European Union's 7th Framework Programme under grant agreement no. NMP3-SL-2010-245993 (GAMBA) and by a National University of Ireland travelling studentship. A.R. is supported by a research fellowship CRF12RYA.

Disclosure Statement

No competing financial interests exist

References

- Loeser, R.F. Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix. *Osteoarthritis Cartilage* **17**, 971, 2009.
- Apold, H., Meyer, H.E., Espehaug, B., Nordsletten, L., Havelin, L.I., and Flugsrud, G.B. Weight gain and the risk of total hip replacement a population-based prospective cohort study of 265,725 individuals. *Osteoarthritis Cartilage* **19**, 809, 2011.
- Roos, E.M. Joint injury causes knee osteoarthritis in young adults. *Curr Opin Rheumatol* **17**, 195, 2005.
- Loeser, R.F., Goldring, S.R., Scanzello, C.R., and Goldring, M.B. Osteoarthritis: a disease of the joint as an organ. *Arthritis Rheum* **64**, 1697, 2012.
- Lories, R.J., and Luyten, F.P. The bone-cartilage unit in osteoarthritis. *Nat Rev Rheumatol* **7**, 43, 2011.
- Yang, S., Kim, J., Ryu, J.H., Oh, H., Chun, C.H., Kim, B.J., Min, B.H., and Chun, J.S. Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. *Nat Med* **16**, 687, 2010.
- Pessler, F., Dai, L., Diaz-Torne, C., Gomez-Vaquero, C., Paessler, M.E., Zheng, D.H., Einhorn, E., Range, U., Scanzello, C., and Schumacher, H.R. The synovitis of "non-inflammatory" orthopaedic arthropathies: a quantitative histological and immunohistochemical analysis. *Ann Rheum Dis* **67**, 1184, 2008.
- Yang, K.G.A., Saris, D.B.F., Verbout, A.J., Creemers, L.B., and Dhert, W.J.A. The effect of synovial fluid from injured knee joints on *in vitro* chondrogenesis. *Tissue Eng* **12**, 2957, 2006.

9. Legendre, F., Dudhia, J., Pujol, J.P., and Bogdanowicz, P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. *J Biol Chem* **278**, 2903, 2003.
10. Dvir-Ginzberg, M., Gagarina, V., Lee, E.J., Booth, R., Gabay, O., and Hall, D.J. Tumor necrosis factor α -mediated cleavage and inactivation of SirT1 in human osteoarthritic chondrocytes. *Arthritis Rheum* **63**, 2363, 2011.
11. Westacott, C.I., Barakat, A.F., Wood, L., Perry, M.J., Neison, P., Bisbinas, I., Armstrong, L., Millar, A.B., and Elson, C.J. Tumor necrosis factor α can contribute to focal loss of cartilage in osteoarthritis. *Osteoarthritis Cartilage* **8**, 213, 2000.
12. Li, X., Ellman, M., Muddasani, P., Wang, J.H., Cs-Szabo, G., van Wijnen, A.J., and Im, H.J. Prostaglandin E2 and its cognate EP receptors control human adult articular cartilage homeostasis and are linked to the pathophysiology of osteoarthritis. *Arthritis Rheum* **60**, 513, 2009.
13. Johnson, K., Hashimoto, S., Lotz, M., Pritzker, K., and Terkeltaub, R. Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. *Am J Pathol* **159**, 149, 2001.
14. Fernandez-Madrid, F., Karvonen, R.L., Teitge, R.A., Miller, P.R., An, T., and Negendank, W.G. Synovial thickening detected by MR imaging in osteoarthritis of the knee confirmed by biopsy as synovitis. *Magn Reson Imaging* **13**, 177, 1995.
15. Steadman, J.R., Briggs, K.K., Rodrigo, J.J., Kocher, M.S., Gill, T.J., and Rodkey, W.G. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. *Arthroscopy* **19**, 477, 2003.
16. Laurencin, C.T., Ambrosio, A.M.A., Borden, M.D., and Cooper, J.A. Tissue engineering: orthopedic applications. *Annu Rev Biomed Eng* **1**, 19, 1999.
17. Emre, T.Y., Ege, T., Kose, O., Tekdos Demircioglu, D., Seyhan, B., and Uzun, M. Factors affecting the outcome of osteochondral autografting (mosaicplasty) in articular cartilage defects of the knee joint: retrospective analysis of 152 cases. *Arch Orthop Trauma Surg* **133**, 531, 2013.
18. Batty, L., Dance, S., Bajaj, S., and Cole, B.J. Autologous chondrocyte implantation: an overview of technique and outcomes. *Anz J Surg* **81**, 18, 2011.
19. Bartlett, W., Skinner, J.A., Gooding, C.R., Carrington, R.W.J., Flanagan, A.M., Briggs, T.W.R., and Bentley, G. Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee. *J Bone Joint Surg Br* **87B**, 640, 2005.
20. Naveen, S., Robson, N., and Kamarul, T. Comparative analysis of autologous chondrocyte implantation and other treatment modalities: a systematic review. *Eur J Orthop Surg Traumatol* **22**, 89, 2012.
21. Basad, E., Ishaque, B., Bachmann, G., Sturz, H., and Steinmeyer, J. Matrix-induced autologous chondrocyte implantation versus microfracture in the treatment of cartilage defects of the knee: a 2-year randomised study. *Knee Surg Sports Traumatol Arthrosc* **18**, 519, 2010.
22. Lee, K.B., Hui, J.H., Song, I.C., Ardany, L., and Lee, E.H. Injectable mesenchymal stem cell therapy for large cartilage defects—a porcine model. *Stem Cells* **25**, 2964, 2007.
23. Fan, H., Hu, Y., Zhang, C., Li, X., Lv, R., Qin, L., and Zhu, R. Cartilage regeneration using mesenchymal stem cells and a PLGA-gelatin/chondroitin/hyaluronate hybrid scaffold. *Biomaterials* **27**, 4573, 2006.
24. Lee, C.H., Cook, J.L., Mendelson, A., Moiola, E.K., Yao, H., and Mao, J.J. Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study. *Lancet* **376**, 440, 2010.
25. Coleman, C.M., Curtin, C., Barry, F.P., O'Flatharta, C., and Murphy, J.M. Mesenchymal stem cells and osteoarthritis: remedy or accomplice? *Hum Gene Ther* **21**, 1239, 2010.
26. Yoo, J.U., Barthel, T.S., Nishimura, K., Solchaga, L., Caplan, A.I., Goldberg, V.M., and Johnstone, B. The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells. *J Bone Joint Surg Am* **80**, 1745, 1998.
27. Murphy, J.M., Fink, D.J., Hunziker, E.B., and Barry, F.P. Stem cell therapy in a caprine model of osteoarthritis. *Arthritis Rheum* **48**, 3464, 2003.
28. Emadeddin, M., Aghdami, N., Taghiyar, L., Fazeli, R., Moghadasali, R., Jahangir, S., Farjad, R., and Baghaban Eslaminejad, M. Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. *Arch Iran Med* **15**, 422, 2012.
29. Davatchi, F., Abdollahi, B.S., Mohyeddin, M., Shahram, F., and Nikbin, B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. *Int J Rheum Dis* **14**, 211, 2011.
30. Orozco, L., Munar, A., Soler, R., Alberca, M., Soler, F., Huguet, M., Sentis, J., Sanchez, A., and Garcia-Sancho, J. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. *Transplantation* **95**, 1535, 2013.
31. Vangsness, C.T., Jr., Farr, J., 2nd, Boyd, J., Dellaero, D.T., Mills, C.R., and LeRoux-Williams, M. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. *J Bone Joint Surg Am* **96**, 90, 2014.
32. Hajishengallis, G., and Lambris, J.D. Microbial manipulation of receptor crosstalk in innate immunity. *Nat Rev Immunol* **11**, 187, 2011.
33. Kabashima, K., Murata, T., Tanaka, H., Matsuoka, T., Sakata, D., Yoshida, N., Katagiri, K., Kinashi, T., Tanaka, T., Miyasaka, M., Nagai, H., Ushikubi, F., and Narumiya, S. Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. *Nat Immunol* **4**, 694, 2003.
34. Pessler, F., Chen, L.X., Dai, L., Gomez-Vaquero, C., Diaz-Torne, C., Paessler, M.E., Scanzello, C., Cakir, N., Einhorn, E., and Schumacher, H.R. A histomorphometric analysis of synovial biopsies from individuals with Gulf War Veterans' Illness and joint pain compared to normal and osteoarthritis synovium. *Clin Rheumatol* **27**, 1127, 2008.
35. Sellam, J., and Berenbaum, F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. *Nat Rev Rheumatol* **6**, 625, 2010.
36. Gelber, A.C., Hochberg, M.C., Mead, L.A., Wang, N.Y., Wigley, F.M., and Klag, M.J. Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. *Ann Intern Med* **133**, 321, 2000.
37. Scanzello, C.R., McKeon, B., Swaim, B.H., DiCarlo, E., Asomugha, E.U., Kanda, V., Nair, A., Lee, D.M., Richmond,

- J.C., Katz, J.N., Crow, M.K., and Goldring, S.R. Synovial inflammation in patients undergoing arthroscopic meniscectomy: molecular characterization and relationship to symptoms. *Arthritis Rheum* **63**, 391, 2011.
38. Beekhuizen, M., Bastiaansen-Jenniskens, Y.M., Koevoet, W., Saris, D.B., Dhert, W.J., Creemers, L.B., and van Osch, G.J. Osteoarthritic synovial tissue inhibits proteoglycan production in human osteoarthritic cartilage; Establishment and characterisation of a long-term coculture. *Arthritis Rheum* **63**, 1918, 2011.
39. Smith, M.D. The normal synovium. *Open Rheumatol J* **5**, 100, 2011.
40. Benito, M.J., Veale, D.J., FitzGerald, O., van den Berg, W.B., and Bresnihan, B. Synovial tissue inflammation in early and late osteoarthritis. *Ann Rheum Dis* **64**, 1263, 2005.
41. Iwanaga, T., Shikichi, M., Kitamura, H., Yanase, H., and Nozawa-Inoue, K. Morphology and functional roles of synoviocytes in the joint. *Arch Histol Cytol* **63**, 17, 2000.
42. Bondeson, J., Blom, A.B., Wainwright, S., Hughes, C., Caterson, B., and van den Berg, W.B. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. *Arthritis Rheum* **62**, 647, 2010.
43. Shakibaei, M., John, T., Schulze-Tanzil, G., Lehmann, I., and Mobasheri, A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclooxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. *Biochem Pharmacol* **73**, 1434, 2007.
44. Jiang, Y.J., Lu, B., Choy, P.C., and Hatch, G.M. Regulation of cytosolic phospholipase A(2), cyclooxygenase-1 and-2 expression by PMA, TNF alpha, LPS and M-CSF in human monocytes and macrophages. *Mol Cell Biochem* **246**, 31, 2003.
45. Wang, X., Li, F., Fan, C., Wang, C., and Ruan, H. Analysis of isoform specific ERK signaling on the effects of interleukin-1beta on COX-2 expression and PGE2 production in human chondrocytes. *Biochem Biophys Res Commun* **402**, 23, 2010.
46. Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J.M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., Manogue, K.R., Faist, E., Abraham, E., Andersson, J., Andersson, U., Molina, P.E., Abumrad, N.N., Sama, A., and Tracey, K.J. HMG-1 as a late mediator of endotoxin lethality in mice. *Science* **285**, 248, 1999.
47. Yang, H., Wang, H., Czura, C.J., and Tracey, K.J. The cytokine activity of HMGB1. *J Leukoc Biol* **78**, 1, 2005.
48. Garcia-Arandis, I., Guillen, M.I., Gomar, F., Pelletier, J.P., Martel-Pelletier, J., and Alcaraz, M.J. High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1beta in osteoarthritic synoviocytes. *Arthritis Res Ther* **12**, R165, 2010.
49. Wahamoa, H., Schierbeck, H., Hreggvidsdottir, H.S., Palmblad, K., Aveberger, A.C., Andersson, U., and Harris, H.E. High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. *Arthritis Res Ther* **13**, R136, 2011.
50. Taniguchi, N., Yoshida, K., Ito, T., Tsuda, M., Mishima, Y., Furumatsu, T., Ronfani, L., Abeyama, K., Kawahara, K., Komiya, S., Maruyama, I., Lotz, M., Bianchi, M.E., and Asahara, H. Stage-specific secretion of HMGB1 in cartilage regulates endochondral ossification. *Mol Cell Biol* **27**, 5650, 2007.
51. Heinola, T., Kouri, V.P., Clarijs, P., Ciferska, H., Sukura, A., Salo, J., and Kontinen, Y.T. High mobility group box-1 (HMGB-1) in osteoarthritic cartilage. *Clin Exp Rheumatol* **28**, 511, 2010.
52. Zoricic, S., Maric, I., Bobinac, D., and Vukicevic, S. Expression of bone morphogenetic proteins and cartilage-derived morphogenetic proteins during osteophyte formation in humans. *J Anat* **202**, 269, 2003.
53. Blom, A.B., van Lent, P.L., Holthuisen, A.E., van der Kraan, P.M., Roth, J., van Rooijen, N., and van den Berg, W.B. Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis. *Osteoarthritis Cartilage* **12**, 627, 2004.
54. van Lent, P.L., Blom, A.B., van der Kraan, P., Holthuisen, A.E., Vitters, E., van Rooijen, N., Smeets, R.L., Nabbe, K.C., and van den Berg, W.B. Crucial role of synovial lining macrophages in the promotion of transforming growth factor beta-mediated osteophyte formation. *Arthritis Rheum* **50**, 103, 2004.
55. Inoue, H., Takamori, M., Nagata, N., Nishikawa, T., Oda, H., Yamamoto, S., and Koshihara, Y. An investigation of cell proliferation and soluble mediators induced by interleukin 1beta in human synovial fibroblasts: comparative response in osteoarthritis and rheumatoid arthritis. *Inflamm Res* **50**, 65, 2001.
56. Kvist, A.J., Nystrom, A., Hultenby, K., Sasaki, T., Talts, J.F., and Aspberg, A. The major basement membrane components localize to the chondrocyte pericellular matrix—a cartilage basement membrane equivalent? *Matrix Biol* **27**, 22, 2008.
57. Felka, T., Warstat, K., Kluba, T., Mittag, F., Hoberg, M., Klein, G., and Aicher, W.K. Transforming growth factor-β1 and laminin-111 cooperate in the regulation of expression of interleukin-6 and interleukin-8 in synovial fibroblasts. *Int J Biomed Sci* **6**, 289, 2010.
58. Lin, Y.M., Hsu, C.J., Liao, Y.Y., Chou, M.C., and Tang, C.H. The CCL2/CCR2 axis enhances vascular cell adhesion molecule-1 expression in human synovial fibroblasts. *PLoS One* **7**, e49999, 2012.
59. Liu, J.F., Hou, S.M., Tsai, C.H., Huang, C.Y., Hsu, C.J., and Tang, C.H. CCN4 induces vascular cell adhesion molecule-1 expression in human synovial fibroblasts and promotes monocyte adhesion. *Biochim Biophys Acta* **1833**, 966, 2013.
60. Renoux, M., Hilliquin, P., Galoppin, L., Florentin, I., and Menkes, C.J. Release of mast cell mediators and nitrites into knee joint fluid in osteoarthritis—comparison with articular chondrocalcinosis and rheumatoid arthritis. *Osteoarthritis Cartilage* **4**, 175, 1996.
61. Nakano, S., Mishiro, T., Takahara, S., Yokoi, H., Hamada, D., Yukata, K., Takata, Y., Goto, T., Egawa, H., Yasuoka, S., Furouchi, H., Hirasaka, K., Nikawa, T., and Yasui, N. Distinct expression of mast cell tryptase and protease activated receptor-2 in synovia of rheumatoid arthritis and osteoarthritis. *Clin Rheumatol* **26**, 1284, 2007.
62. Kiener, H.P., Hofbauer, R., Tohidast-Akrad, M., Walchshofer, S., Redlich, K., Bitzan, P., Kapiotis, S., Steiner, G., Smolen, J.S., and Valent, P. Tumor necrosis factor alpha promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. *Arthritis Rheum* **43**, 164, 2000.
63. Buckley, M.G., Gallagher, P.J., and Walls, A.F. Mast cell subpopulations in the synovial tissue of patients with

- osteoarthritis: selective increase in numbers of tryptase-positive, chymase-negative mast cells. *J Pathol* **186**, 67, 1998.
64. Schwartz, L.B., Lewis, R.A., Seldin, D., and Austen, K.F. Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells. *J Immunol* **126**, 1290, 1981.
 65. Cairns, J.A., and Walls, A.F. Mast cell tryptase is a mitogen for epithelial cells—stimulation of IL-8 production and intercellular adhesion molecule-1 expression. *J Immunol* **156**, 275, 1996.
 66. Compton, S.J., Cairns, J.A., Holgate, S.T., and Walls, A.F. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1 beta and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. *J Immunol* **161**, 1939, 1998.
 67. Carroll, M.V., and Sim, R.B. Complement in health and disease. *Adv Drug Deliv Rev* **63**, 965, 2011.
 68. Wang, Q., Rozelle, A.L., Lepus, C.M., Scanzello, C.R., Song, J.J., Larsen, D.M., Crish, J.F., Bebek, G., Ritter, S.Y., Lindstrom, T.M., Hwang, I., Wong, H.H., Punzi, L., Encarnacion, A., Shamloo, M., Goodman, S.B., Wyss-Coray, T., Goldring, S.R., Banda, N.K., Thurman, J.M., Gobeze, R., Crow, M.K., Holers, V.M., Lee, D.M., and Robinson, W.H. Identification of a central role for complement in osteoarthritis. *Nat Med* **17**, 1674, 2011.
 69. Ritter, S.Y., Subbaiah, R., Bebek, G., Crish, J., Scanzello, C.R., Krastins, B., Sarracino, D., Lopez, M.F., Crow, M.K., Aigner, T., Goldring, M.B., Goldring, S.R., Lee, D.M., Gobeze, R., and Aliprantis, A.O. Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues. *Arthritis Rheum* **65**, 981, 2013.
 70. Nakamura, H., Yoshino, S., Kato, T., Tsuruha, J., and Nishioka, K. T-cell mediated inflammatory pathway in osteoarthritis. *Osteoarthritis Cartilage* **7**, 401, 1999.
 71. Sakkas, L.I., Scanzello, C., Johanson, N., Burkholder, J., Mitra, A., Salgame, P., Katsetos, C.D., and Platsoucas, C.D. T cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritis. *Clin Diagn Lab Immunol* **5**, 430, 1998.
 72. Santana, M.A., and Rosenstein, Y. What it takes to become an effector T cell: the process, the cells involved, and the mechanisms. *J Cell Physiol* **195**, 392, 2003.
 73. Mosmann, T.R., and Coffman, R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* **7**, 145, 1989.
 74. Munegowda, M.A., Xu, S.L., Freywald, A., and Xiang, J. CD4(+) Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene. *Mol Immunol* **51**, 143, 2012.
 75. Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A., and Coffman, R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* **136**, 2348, 1986.
 76. Ishii, H., Tanaka, H., Katoh, K., Nakamura, H., Nagashima, M., and Yoshino, S. Characterization of infiltrating T cells and Th1/Th2-type cytokines in the synovium of patients with osteoarthritis. *Osteoarthritis Cartilage* **10**, 277, 2002.
 77. Haywood, L., McWilliams, D.F., Pearson, C.I., Gill, S.E., Ganesan, A., Wilson, D., and Walsh, D.A. Inflammation and angiogenesis in osteoarthritis. *Arthritis Rheum* **48**, 2173, 2003.
 78. Koch, A.E., Harlow, L.A., Haines, G.K., Amento, E.P., Unemori, E.N., Wong, W.L., Pope, R.M., and Ferrara, N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. *J Immunol* **152**, 4149, 1994.
 79. Connolly, D.T. Vascular permeability factor: a unique regulator of blood vessel function. *J Cell Biochem* **47**, 219, 1991.
 80. Ludin, A., Sela, J.J., Schroeder, A., Samuni, Y., Nitzan, D.W., and Amir, G. Injection of vascular endothelial growth factor into knee joints induces osteoarthritis in mice. *Osteoarthritis Cartilage* **21**, 491, 2013.
 81. Lindsley, H.B., Smith, D.D., Cohick, C.B., Koch, A.E., and Davis, L.S. Proinflammatory cytokines enhance human synovial cell expression of functional intercellular adhesion molecule-1 (ICAM-1). *Clin Immunol Immunopathol* **68**, 311, 1993.
 82. Oppenheimer-Marks, N., Davis, L.S., Bogue, D.T., Ramberg, J., and Lipsky, P.E. Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. *J Immunol* **147**, 2913, 1991.
 83. Shen, P.C., Wu, C.L., Jou, I.M., Lee, C.H., Juan, H.Y., Lee, P.J., Chen, S.H., and Hsieh, J.L. T helper cells promote disease progression of osteoarthritis by inducing macrophage inflammatory protein-1gamma. *Osteoarthritis Cartilage* **19**, 728, 2011.
 84. de Jong, H., Berlo, S.E., Hombrink, P., Otten, H.G., van Eden, W., Lafey, F.P., Heurkens, A.H., Bijlsma, J.W., Gant, T.T., and Prakken, B.J. Cartilage proteoglycan aggrecan epitopes induce proinflammatory autoreactive T-cell responses in rheumatoid arthritis and osteoarthritis. *Ann Rheum Dis* **69**, 255, 2010.
 85. Zhang, W., Moskowitz, R.W., Nuki, G., Abramson, S., Altman, R.D., Arden, N., Bierma-Zeinstra, S., Brandt, K.D., Croft, P., Doherty, M., Dougados, M., Hochberg, M., Hunter, D.J., Kwoh, K., Lohmander, L.S., and Tugwell, P. OARS recommendations for the management of hip and knee osteoarthritis, Part II: OARS evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage* **16**, 137, 2008.
 86. Gallelli, L., Galasso, O., Falcone, D., Southworth, S., Greco, M., Ventura, V., Romualdi, P., Corigliano, A., Terracciano, R., Savino, R., Gulletta, E., Gasparini, G., and De Sarro, G. The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial. *Osteoarthritis Cartilage* **21**, 1400, 2013.
 87. Watson, D.J., Yu, Q., Bolognese, J.A., Reicin, A.S., and Simon, T.J. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. *Curr Med Res Opin* **20**, 1539, 2004.
 88. Caldwell, B., Aldington, S., Weatherall, M., Shirtcliffe, P., and Beasley, R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. *J R Soc Med* **99**, 132, 2006.
 89. Reijman, M., Bierma-Zeinstra, S.M.A., Pols, H.A.P., Koes, B.W., Stricker, B.H.C., and Hazes, J.M.W. Is there an association between the use of different types of non-steroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam study. *Arthritis Rheum* **52**, 3137, 2005.

90. Dingle, J.T. The effect of nonsteroidal antiinflammatory drugs on human articular cartilage glycosaminoglycan synthesis. *Osteoarthritis Cartilage* **7**, 313, 1999.
91. Ou, Y.S., Tan, C., An, H., Jiang, D.M., Quan, Z.X., Tang, K., and Luo, X.J. The effects of NSAIDs on types I, II, and III collagen metabolism in a rat osteoarthritis model. *Rheumatol Int* **32**, 2401, 2012.
92. Verbruggen, G., Wittoek, R., Vander Cruyssen, B., and Elewaut, D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. *Ann Rheum Dis* **71**, 891, 2012.
93. Maksymowych, W.P., Russell, A.S., Chiu, P., Yan, A., Jones, N., Clare, T., and Lambert, R.G. Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. *Arthritis Res Ther* **14**, R206, 2012.
94. Bartels, E.M., Bliddal, H., Schondorff, P.K., Altman, R.D., Zhang, W., and Christensen, R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. *Osteoarthritis Cartilage* **18**, 289, 2010.
95. Rintelen, B., Neumann, K., and Leeb, B.F. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. *Arch Intern Med* **166**, 1899, 2006.
96. Chevalier, X., Goupille, P., Beaulieu, A.D., Burch, F.X., Bensen, W.G., Conrozier, T., Loeuille, D., Kivitz, A.J., Silver, D., and Appleton, B.E. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum* **61**, 344, 2009.
97. Roszer, T. Inflammation as death or life signal in diabetic fracture healing. *Inflamm Res* **60**, 3, 2011.
98. Scotti, C., Osmokrovic, A., Wolf, F., Miot, S., Peretti, G.M., Barbero, A., and Martin, I. Response of human engineered cartilage based on articular or nasal chondrocytes to interleukin-1 β and low oxygen. *Tissue Eng Part A* **18**, 362, 2012.
99. Djouad, F., Rackwitz, L., Song, Y.J., Janjanin, S., and Tuan, R.S. ERK1/2 activation induced by inflammatory cytokines compromises effective host tissue integration of engineered cartilage. *Tissue Eng Pt A* **15**, 2825, 2009.
100. Joos, H., Wildner, A., Hogrefe, C., Reichel, H., and Brenner, R.E. Interleukin-1 β and tumor necrosis factor α inhibit migration activity of chondrogenic progenitor cells from non-fibrillated osteoarthritic cartilage. *Arthritis Res Ther* **15**, R119, 2013.
101. Wehling, N., Palmer, G.D., Pilapil, C., Liu, F., Wells, J.W., Muller, P.E., Evans, C.H., and Porter, R.M. Interleukin-1 β and tumor necrosis factor α inhibit chondrogenesis by human mesenchymal stem cells through NF-kappaB-dependent pathways. *Arthritis Rheum* **60**, 801, 2009.
102. Ousema, P.H., Moutos, F.T., Estes, B.T., Caplan, A.I., Lennon, D.P., Guilak, F., and Weinberg, J.B. The inhibition by interleukin 1 of MSC chondrogenesis and the development of biomechanical properties in biomimetic 3D woven PCL scaffolds. *Biomaterials* **33**, 8967, 2012.
103. Heldens, G.T., Blaney Davidson, E.N., Vitters, E.L., Schreurs, B.W., Piek, E., van den Berg, W.B., and van der Kraan, P.M. Catabolic factors and osteoarthritis-conditioned medium inhibit chondrogenesis of human mesenchymal stem cells. *Tissue Eng Part A* **18**, 45, 2012.
104. Kruger, J.P., Endres, M., Neumann, K., Stuhlmuller, B., Morawietz, L., Haupl, T., and Kaps, C. Chondrogenic differentiation of human subchondral progenitor cells is affected by synovial fluid from donors with osteoarthritis or rheumatoid arthritis. *J Orthop Surg Res* **7**, 10, 2012.
105. Anderson, J.M., Rodriguez, A., and Chang, D.T. Foreign body reaction to biomaterials. *Semin Immunol* **20**, 86, 2008.
106. Grotenhuis, N., Bayon, Y., Lange, J.F., Van Osch, G.J., and Bastiaansen-Jenniskens, Y.M. A culture model to analyze the acute biomaterial-dependent reaction of human primary macrophages. *Biochem Biophys Res Commun* **433**, 115, 2013.
107. Matesanz, M.C., Feito, M.J., Onaderra, M., Ramirez-Santillan, C., da Casa, C., Arcos, D., Vallet-Regi, M., Rojo, J.M., and Portoles, M.T. Early *in vitro* response of macrophages and T lymphocytes to nanocrystalline hydroxyapatites. *J Colloid Interface Sci* **416**, 59, 2014.
108. Go, D.P., Palmer, J.A., Gras, S.L., and O'Connor, A.J. Coating and release of an anti-inflammatory hormone from PLGA microspheres for tissue engineering. *J Biomed Mater Res Part A* **100A**, 507, 2012.
109. Matsumoto, T., Cooper, G.M., Gharaibeh, B., Meszaros, L.B., Li, G., Usas, A., Fu, F.H., and Huard, J. Cartilage repair in a rat model of osteoarthritis through intraarticular transplantation of muscle-derived stem cells expressing bone morphogenetic protein 4 and soluble Flt-1. *Arthritis Rheum* **60**, 1390, 2009.
110. Caplan, A.I., and Dennis, J.E. Mesenchymal stem cells as trophic mediators. *J Cell Biochem* **98**, 1076, 2006.
111. van Buul, G.M., Villafuertes, E., Bos, P.K., Waarsing, J.H., Kops, N., Narcisi, R., Weinans, H., Verhaar, J.A., Bernsen, M.R., and van Osch, G.J. Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture. *Osteoarthritis Cartilage* **20**, 1186, 2012.
112. Yang, S.H., Park, M.J., Yoon, I.H., Kim, S.Y., Hong, S.H., Shin, J.Y., Nam, H.Y., Kim, Y.H., Kim, B., and Park, C.G. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. *Exp Mol Med* **41**, 315, 2009.
113. English, K., French, A., and Wood, K.J. Mesenchymal stromal cells: facilitators of successful transplantation? *Cell Stem Cell* **7**, 431, 2010.
114. Brown, J.M., Nemeth, K., Kushnir-Sukhov, N.M., Metcalfe, D.D., and Mezey, E. Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. *Clin Exp Allergy* **41**, 526, 2011.
115. Mosser, D.M., and Edwards, J.P. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol* **8**, 958, 2008.
116. Kim, J., and Hematti, P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. *Exp Hematol* **37**, 1445, 2009.
117. Zhang, Q.Z., Su, W.R., Shi, S.H., Wilder-Smith, P., Xiang, A.P., Wong, A., Nguyen, A.L., Kwon, C.W., and Le, A.D. Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. *Stem Cells* **28**, 1856, 2010.
118. Holladay, C., Power, K., Sefton, M., O'Brien, T., Gallagher, W.M., and Pandit, A. Functionalized scaffold-mediated interleukin 10 gene delivery significantly improves survival rates of stem cells *in vivo*. *Mol Ther* **19**, 969, 2011.
119. Dieckman, B.O., Wu, C.L., Louer, C.R., Furman, B.D., Huebner, J.L., Kraus, V.B., Olson, S.A., and Guilak, F.

- Intra-articular delivery of purified mesenchymal stem cells from C57BL/6 or MRL/MpJ superhealer mice prevents posttraumatic arthritis. *Cell Transplant* **22**, 1395, 2013.
120. ter Huurne, M., Schelbergen, R., Blattes, R., Blom, A., de Munter, W., Grevers, L.C., Jeanson, J., Noel, D., Casteilla, L., Jorgensen, C., van den Berg, W., and van Lent, P.L. Antiinflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis. *Arthritis Rheum* **64**, 3604, 2012.
 121. Desando, G., Cavallo, C., Sartoni, F., Martini, L., Parrilli, A., Veronesi, F., Fini, M., Giardino, R., Facchini, A., and Grigolo, B. Intra-articular delivery of adipose derived stromal cells attenuates osteoarthritis progression in an experimental rabbit model. *Arthritis Res Ther* **15**, R22, 2013.
 122. Takahashi, K., and Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **126**, 663, 2006.
 123. Diekman, B.O., Christoforou, N., Willard, V.P., Sun, H., Sanchez-Adams, J., Leong, K.W., and Guilak, F. Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells. *Proc Natl Acad Sci U S A* **109**, 19172, 2012.
 124. Guzzo, R.M., Gibson, J., Xu, R.H., Lee, F.Y., and Drissi, H. Efficient differentiation of human iPSC-derived mesenchymal stem cells to chondroprogenitor cells. *J Cell Biochem* **114**, 480, 2013.
 125. Sun, Y.Q., Deng, M.X., He, J., Zeng, Q.X., Wen, W., Wong, D.S., Tse, H.F., Xu, G., Lian, Q., Shi, J., and Fu, Q.L. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. *Stem Cells* **30**, 2692, 2012.
 126. Fu, Q.L., Chow, Y.Y., Sun, S.J., Zeng, Q.X., Li, H.B., Shi, J.B., Sun, Y.Q., Wen, W., Tse, H.F., Lian, Q., and Xu, G. Mesenchymal stem cells derived from human induced pluripotent stem cells modulate T-cell phenotypes in allergic rhinitis. *Allergy* **67**, 1215, 2012.
 127. Stolzinger, A., Jones, E., McGonagle, D., and Scutt, A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. *Mech Ageing Dev* **129**, 163, 2008.
 128. Hart, P.H., Ahern, M.J., Smith, M.D., and Finlay-Jones, J.J. Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis. *Immunology* **84**, 536, 1995.
 129. Joosten, L.A., Lubberts, E., Durez, P., Helsen, M.M., Jacobs, M.J., Goldman, M., and van den Berg, W.B. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. *Arthritis Rheum* **40**, 249, 1997.
 130. van Meegeren, M.E., Roosendaal, G., Jansen, N.W., Wenting, M.J., van Wesel, A.C., van Roon, J.A., and Lafeber, F.P. IL-4 alone and in combination with IL-10 protects against blood-induced cartilage damage. *Osteoarthritis Cartilage* **20**, 764, 2012.
 131. Yorimitsu, M., Nishida, K., Shimizu, A., Doi, H., Miyazawa, S., Komiyama, T., Nasu, Y., Yoshida, A., Watanabe, S., and Ozaki, T. Intra-articular injection of interleukin-4 decreases nitric oxide production by chondrocytes and ameliorates subsequent destruction of cartilage in instability-induced osteoarthritis in rat knee joints. *Osteoarthritis Cartilage* **16**, 764, 2008.
 132. Cao, L., Yang, F., Liu, G., Yu, D., Li, H., Fan, Q., Gan, Y., Tang, T., and Dai, K. The promotion of cartilage defect repair using adenovirus mediated Sox9 gene transfer of rabbit bone marrow mesenchymal stem cells. *Biomaterials* **32**, 3910, 2011.
 133. Frisbie, D.D., Ghivizzani, S.C., Robbins, P.D., Evans, C.H., and McIlwraith, C.W. Treatment of experimental equine osteoarthritis by *in vivo* delivery of the equine interleukin-1 receptor antagonist gene. *Gene Ther* **9**, 12, 2002.
 134. Zhang, X., Mao, Z., and Yu, C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. *J Orthop Res* **22**, 742, 2004.
 135. Fernandes, J., Tardif, G., Martel-Pelletier, J., Lascau-Coman, V., Dupuis, M., Moldovan, F., Sheppard, M., Krishnan, B.R., and Pelletier, J.P. *In vivo* transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. *Am J Pathol* **154**, 1159, 1999.
 136. Pelletier, J.P., Caron, J.P., Evans, C., Robbins, P.D., Georgescu, H.I., Jovanovic, D., Fernandes, J.C., and Martel-Pelletier, J. *In vivo* suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. *Arthritis Rheum* **40**, 1012, 1997.
 137. Noh, M.J., Copeland, R.O., Yi, Y., Choi, K.B., Meschter, C., Hwang, S., Lim, C.L., Yip, V., Hyun, J.P., Lee, H.Y., and Lee, K.H. Pre-clinical studies of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 (TG-C). *Cytotherapy* **12**, 384, 2010.
 138. Scharstuhl, A., Glansbeek, H.L., van Beuningen, H.M., Vitters, E.L., van der Kraan, P.M., and van den Berg, W.B. Inhibition of endogenous TGF-beta during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. *J Immunol* **169**, 507, 2002.
 139. Zhen, G.H., Wen, C.Y., Jia, X.F., Li, Y., Crane, J.L., Mears, S.C., Askin, F.B., Frassica, F.J., Chang, W.Z., Yao, J., Carriano, J.A., Cosgarea, A., Artemov, D., Chen, Q.M., Zhao, Z.H., Zhou, X.D., Riley, L., Sponseller, P., Wan, M., Lu, W.W., and Cao, X. Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. *Nature Medicine* **19**, 704, 2013.

Address correspondence to:

J. Mary Murphy, PhD

Regenerative Medicine Institute

National University of Ireland Galway

Galway

Ireland

E-mail: mary.murphy@nuigalway.ie

Received: February 5, 2014

Accepted: June 19, 2014

Online Publication Date: August 1, 2014